Chronic desensitization to bombesin by progressive down-regulation of bombesin receptors in Swiss 3T3 cells. Distinction from acute desensitization
- PMID: 2164025
Chronic desensitization to bombesin by progressive down-regulation of bombesin receptors in Swiss 3T3 cells. Distinction from acute desensitization
Abstract
Prolonged exposure (40 h) of Swiss 3T3 cells to bombesin induced homologous desensitization to bombesin and structurally related peptides including mammalian gastrin releasing peptide (GRP). The ability of bombesin to mobilize intracellular Ca2+, inhibit epidermal growth factor binding, and stimulate DNA synthesis was profoundly and selectively inhibited. In contrast, Ca2+ mobilization by either vasopressin or bradykinin was unaffected, indicating that chronic desensitization is mechanistically distinct from acute desensitization of Ca2+ mobilization. Prolonged (24 or 40 h) pretreatment with bombesin also induced a 78 +/- 5% loss of bombesin receptor binding sites in both intact and plasma membrane preparations of Swiss 3T3 cells without an apparent change in receptor affinity (Kd = 1.9 +/- 0.1 x 10(-9) M and Kd = 1.8 +/- 0.2 x 10(-9) M for control and pretreated cells, respectively). Loss of 125I-GRP binding was slow and progressive with half-maximal loss of binding occurring after 7 h and maximal after approximately 14 h. Cross-linking of 125I-GRP to intact cultures and membrane preparations revealed an identical time-dependent loss of the Mr = 75,000-85,000 cross-linked band, previously identified as the bombesin receptor. Prolonged exposure of the cells to phorbol 12,13-dibutyrate, epidermal growth factor, cholera toxin, or mitogenic combinations of these agents did not alter 125I-GRP binding. Receptor down-regulation and loss of mitogenic responsiveness to bombesin were: (a) induced in a parallel dose-dependent manner by bombesin (ED50 = 1 nM), GRP (ED50 = 2 nM), and neuromedin B (ED50 = 20 nM), but not by the biologically inactive fragment GRP (1-16); (b) inhibited by the specific bombesin antagonist [Leu13-psi(CH2NH)-Leu14] bombesin, and (c) reversed upon removal of bombesin with a similar time course (full recovery after 15 h). On the basis of these observations, we propose that prolonged pretreatment of Swiss 3T3 cells with bombesin induces homologous desensitization to peptides of the bombesin family by down-regulation of cell surface bombesin receptors.
Similar articles
-
Arachidonic acid release by bombesin. A novel postreceptor target for heterologous mitogenic desensitization.J Biol Chem. 1990 Nov 15;265(32):19973-9. J Biol Chem. 1990. PMID: 2174059
-
Bombesin receptor in membranes from Swiss 3T3 cells. Binding characteristics, affinity labelling and modulation by guanine nucleotides.Biochem J. 1990 Jan 15;265(2):485-93. doi: 10.1042/bj2650485. Biochem J. 1990. PMID: 2154190 Free PMC article.
-
Early events elicited by bombesin and structurally related peptides in quiescent Swiss 3T3 cells. I. Activation of protein kinase C and inhibition of epidermal growth factor binding.J Cell Biol. 1986 Jun;102(6):2211-22. doi: 10.1083/jcb.102.6.2211. J Cell Biol. 1986. PMID: 3011811 Free PMC article.
-
Bombesin stimulation of mitogenesis. Specific receptors, signal transduction, and early events.Am Rev Respir Dis. 1990 Dec;142(6 Pt 2):S11-5. doi: 10.1164/ajrccm/142.6_Pt_2.S11. Am Rev Respir Dis. 1990. PMID: 2174658 Review.
-
Recent advances in the biology of bombesin-like peptides and their receptors.Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):232-237. doi: 10.1097/MED.0000000000000606. Curr Opin Endocrinol Diabetes Obes. 2021. PMID: 33394718 Review.
Cited by
-
GRPR-targeting radiotheranostics for breast cancer management.Front Med (Lausanne). 2023 Nov 3;10:1250799. doi: 10.3389/fmed.2023.1250799. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38020178 Free PMC article. Review.
-
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.Pharmacol Rev. 2008 Mar;60(1):1-42. doi: 10.1124/pr.107.07108. Epub 2007 Nov 30. Pharmacol Rev. 2008. PMID: 18055507 Free PMC article. Review.
-
Evaluation of ABD-Linked RM26 Conjugates for GRPR-Targeted Drug Delivery.ACS Omega. 2024 Aug 15;9(34):36122-36133. doi: 10.1021/acsomega.4c00489. eCollection 2024 Aug 27. ACS Omega. 2024. PMID: 39220525 Free PMC article.
-
Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics.Biomolecules. 2023 Jul 14;13(7):1134. doi: 10.3390/biom13071134. Biomolecules. 2023. PMID: 37509170 Free PMC article.
-
Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.Pharmaceutics. 2019 Jul 23;11(7):358. doi: 10.3390/pharmaceutics11070358. Pharmaceutics. 2019. PMID: 31340483 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous